E best use of clopidogrel supervisor Rocuronium mAChRs inhibitor Ttigungsdosis to reduce recurrent events / organization strategies ish Mix syndromes study, syn the 25.086 patients with acute coronary syndromes, were found closed assess that 30 days after treatment with aspirin 300 to 325 mg / d was more effective than aspirin 75-100 mg / d for the Pr prevention of stroke, MI or kardiovaskul rer death. 48 Thus, based on the results of randomized trials comparing different doses of aspirin, there is no convincing evidence that h Higher doses effective in reducing the risk of serious vascular Ren events than lower doses. In fact, the indirect comparisons reported in the overview of the Antithrombotic Trialists The cooperation and the results of several randomized, direct comparisons are consistent with the inverse of the hei t, it is the antithrombotic effect of blunting with h Higher doses of aspirin, nding afi consistent and dose- Independent inhibition of PGIbeen an untreated control group in a number of thrombotic vascular Ren diseases. Doses of aspirin ranged from 50 to 1500 mg / d aspirin has been shown to be effective under the following conditions: unstable angina pectoris, where the incidence of acute MI or death was reduced by FA signifi cant in four separate studies with matched t Doses of 75, 36 325, 49 650, 50 or 51 mg 1300, stable angina pectoris, where a dose of 75 mg / day reduced the incidence of acute myocardial infarction or pl relooking death 37, CABG surgery, where the incidence of early graft occlusion was also with t adjusted doses of 100, 52 325, 53 975, 54 or 54 mg 1200, thrombosis prophylaxis in patients with artificial heart valves, which also reduced again u warfarin where the H FREQUENCY of systemic embolism was reduced with daily doses of 100, 55 500, 56 or 1500 mg 57.58, thrombosis prophylaxis in H hemodialysis patients with long term shunts, where a dose of 160 mg / day was found to effectively than 59, acute myocardial infarction, in which a dose of 162.5 mg / day reduces the mortality t 35 days and not t more harmful myocardial infarction and 60 stroke, transient isch chemical attack in which doses ranging from 50 to 1200 mg / d were effective acute 38,40,42,61 63 ish mix stroke in which doses of 160 to 300 mg / day were effective in reducing early mortality t and recurrent stroke, 64,65, and Polyzyth chemistry cause, in which 100 mg / d, 41 but not 900 mg / d, 66 was effective in reducing t more harmful and not t more harmful vascular re events. Thus aspirin is effective antithrombotic agent in doses of between 50 and 1500 mg / day. Based on the results of the Dutch Ndischen TIA study, it is also Possible that 30 mg / day is effective. 47 effect of aspirin on gastrointestinal side effects and bleeding: There is evidence that the gastrointestinal side effects of aspirin are dose-ngig. Thus, doses of aspirin 300 mg / d, with fewer gastrointestinal side effects than doses of 1200 mg / d associated. 42 There is also evidence that doses of aspirin are 100 mg / d, with fewer side effects than 300 mg / d in combination. 47 In an analysis of the observations in patients with ACS, the Clopidogrel in Unstable angina Recurrent Events high throughput screening Investigators Prevent shown that aspirin was associated with 100 mg / day alone or in combination with clopidogrel with increased Hten the lower gr Ere or life-threatening bleeding complications than aspirin alone at a dose of 200 mg / d 67 In the current OASIS 7 randomized study, aspirin administered at a dose of 75-100.